

CLAIMS

What is claimed is:

- 5 1. A method for the treatment of B cell disorders comprising the step of
administering a therapeutically effective amount of at least one immunologically
active, chimeric anti-CD20 antibody to a primate.
2. The method of claim 1 wherein the amount of said antibody administered to
10 said primate is between about 0.001 to about 30 milligrams of antibody per
kilogram body weight of said primate ("mg/kg").
3. The method of claim 1 wherein said antibody is derived from a transfectoma
comprising anti-CD20 in TCAE 8 as deposited with the American Tissue Culture
15 Collection as part of ATCC deposit number 69119.
- o 4. The method of claim ^{1 further}~~1 further~~ comprising the step of administering a second
therapeutically effective amount of at least one immunologically active, chimeric
anti-CD20 antibody.
- 20 5. The method of claim 4 wherein said additional administration of said
antibody to said primate occurs within about seven days of said first administration
of said antibody to said primate.

6. A method for the treatment of B cell disorders comprising the steps of:
- 1) administering, at a first administration period, a first therapeutically effective amount of immunologically active, chimeric anti-CD20 antibody to a primate;
 - 2) administering at a second subsequent administration period, a second therapeutically effective amount of said antibody;
 - 3) administering, at a third subsequent administration period, a third therapeutically effective amount of said antibody.
7. The method of claim 6 wherein said first, second and third therapeutically effective amount of said antibody is between about 0.001 mg/kg to about 30 mg/kg.
8. The method of claim 6 wherein said second administration period is within about seven days of said first administration period.
9. The method of claim 6 wherein said third administration period is within about fourteen days of said first administration period.
10. The method of claim 6 wherein said antibody is derived from a transfectoma comprising anti-CD20 in TCAE 8 (within ATCC deposit number 69119).
11. Immunologically active, chimeric anti-CD20 produced from a transfectoma comprising anti-CD20 in TCAE 8 (within ATCC deposit number 69119).